Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc (BRNS) Stock Overview
Explore Barinthus Biotherapeutics plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
24.5M
P/E Ratio
-0.37
EPS (TTM)
$-1.64
ROE
-0.71%
BRNS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Barinthus Biotherapeutics plc (BRNS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 50.21, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.37 and a market capitalization of 24.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.